Imatilek

Imatinib, the active ingredient in Imatilek, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatilek as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatilek (imatinib) is used in hematologic and solid‑tumor malignancies driven by BCR‑ABL or related tyrosine kinases.

- Chronic myeloid leukemia (CML): improves survival by inhibiting BCR‑ABL driven proliferation. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission through targeted kinase blockade. - Gastrointestinal stromal tumor (GIST): reduces tumor growth by targeting c‑KIT and PDGFR signaling.

Imatilek may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools that may require hydration. - Fatigue: generalized tiredness. - Edema: swelling of extremities, especially ankles.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: decreased left ventricular ejection fraction or heart failure. - Severe neutropenia: markedly low white blood cell count increasing infection risk.

When prescribing Imatilek, clinicians should consider several safety precautions.

- Baseline assessment: obtain complete blood count and liver function tests before initiation. - Monitoring: perform regular CBC and hepatic panels during therapy. - Cardiac evaluation: assess cardiac function in patients with pre‑existing heart disease. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Imatilek interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels, risking toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower imatinib exposure, reducing efficacy. - Antacids containing aluminum or magnesium: can reduce absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly affect imatinib absorption; separate dosing by at least 2 hours. - Warfarin: imatinib may enhance anticoagulant effect; monitor INR closely. - CYP2C8 substrates (e.g., repaglinide): possible altered metabolism; adjust dose if needed.